Yamamoto C, Minakata D, Yokoyama D, et al. Cost-effectiveness of anti-bcma chimeric antigen receptor t cell therapy in relapsed/refractory multiple myeloma. The gene discussed is TNFRSF17; the disease is plasma cell myeloma.